Zavegepant: First Approval

被引：22
作者：
Dhillon, Sohita [1 ]
机构：
[1] Springer Nat, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand
来源：
DRUGS | 2023年 / 83卷 / 09期
关键词：
NASAL SPRAY; PHARMACOKINETICS; SINGLE; MIGRAINE; SAFETY; MG;
D O I：
10.1007/s40265-023-01885-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Zavegepant is a third generation, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Pfizer, under a license from Bristol-Myers Squibb, for the prevention and treatment of chronic and episodic migraine. In March 2023, zavegepant nasal spray (ZAVZPRET (TM)) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. Clinical development of an oral formulation of zavegepant is currently underway. This article summarizes the milestones in the development of zavegepant leading to this first approval for the acute treatment of migraine with or without aura in adults.
引用
收藏
页码：825 / 831
页数：7
相关论文
共 26 条
  • [11] Biohaven Pharmaceutical Holding C, 2021, BIOH PFIZ ENT STRAT
  • [12] Biohaven Pharmaceutical Holding Company, 2018, BIOH RESTR LIC AGR B
  • [13] Biohaven Pharmaceutical Holding Company Ltd, 2020, FORM K 10
  • [14] Biohaven Pharmaceutical Holding Company Ltd Bristol-Myers Squibb Company, 2016, LIC AGR BIOH PHARM H
  • [15] Biohaven Pharmaceutical Holding Company Ltd Royalty Pharma, 2018, BIOH ROYALT PHARM AN
  • [16] Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): A potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery
    Chaturvedula, Prasad V.
    Mercer, Stephen E.
    Pin, Sokhom S.
    Thalody, George
    Xu, Cen
    Conway, Charlie M.
    Keavy, Deborah
    Signor, Laura
    Cantor, Glenn H.
    Mathias, Neil
    Moench, Paul
    Denton, Rex
    Macci, Robert
    Schartman, Richard
    Whiterock, Valerie
    Davis, Carl
    Macor, John E.
    Dubowchik, Gene M.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) : 3157 - 3161
  • [17] Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
    Cohen, Fred
    Yuan, Hsiangkuo
    Silberstein, Stephen D.
    [J]. BIODRUGS, 2022, 36 (03) : 341 - 358
  • [18] Comisar CM, 2022, CEPHALALGIA, V42, P53
  • [19] Croop R., 2022, J HEADACHE PAIN, V23, P59
  • [20] Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial
    Croop, Robert
    Madonia, Jennifer
    Stock, David A.
    Thiry, Alexandra
    Forshaw, Micaela
    Murphy, Abigail
    Coric, Vladimir
    Lipton, Richard B.
    [J]. HEADACHE, 2022, 62 (09): : 1153 - 1163
123